Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Themis MedicareNSE:THEMISMED -1.99%74 Return-on-Tangible-Equity is 8.92% as of Mar. 2026, which is 27% below its 10-year median of 12.29. GuruFocus rates NSE:THEMISMED with a GF Score™ of 74/100 and a GF Value™ of ₹149.38 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 900 Drug Manufacturers companies, Themis Medicare ranks worse than 70.56% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Themis Medicare's annualized net income for the quarter that ended in Mar. 2026 was ₹355 Mil. Themis Medicare's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹3,985 Mil. Therefore, Themis Medicare's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 8.92%.
The historical rank and industry rank for Themis Medicare's Return-on-Tangible-Equity or its related term are showing as below:
NSE:THEMISMED'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -6.64 Med: 12.29 Max: 28.93
Current: 0.29
During the past 13 years, Themis Medicare's highest Return-on-Tangible-Equity was 28.93%. The lowest was -6.64%. And the median was 12.29%.
NSE:THEMISMED's Return-on-Tangible-Equity is ranked worse than 70.56% of 900
companies
in the Drug Manufacturers industry
Industry Median: 7.895
vs NSE:THEMISMED: 0.29
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Themis Medicare Return-on-Tangible-Equity Related Terms
Themis Medicare Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Themis Medicare's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:THEMISMED vs ZTS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Themis Medicare's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Themis Medicare Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Themis Medicare's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Themis Medicare's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 8.92% mean?
Themis Medicare (NSE:THEMISMED) has a Return-on-Tangible-Equity of 8.92% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Themis Medicare and its competitors. This is 27% below median its historical median of 12.29. According to the industry distribution chart, Themis Medicare ranks #635 out of 900 companies in the Drug Manufacturers industry, placing it in the top 70.6%.
Is Themis Medicare's Return-on-Tangible-Equity too high?
Themis Medicare's current Return-on-Tangible-Equity of 8.92% is 27% below median its 10-year median of 12.29. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. Themis Medicare's value of 8.92% is 13% above this industry median. Based on the distribution chart, Themis Medicare ranks #635 out of 900 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Themis Medicare has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Themis Medicare's Return-on-Tangible-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Themis Medicare ranks #635 out of 900 companies for Return-on-Tangible-Equity. This places Themis Medicare in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.90. Themis Medicare's value of 8.92% is 13% above this benchmark. While the company's 10-year median is 12.29 vs. the industry median of 7.90, Themis Medicare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 900 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Themis Medicare's current Return-on-Tangible-Equity of 8.92% is 13% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Themis Medicare and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Themis Medicare's current Return-on-Tangible-Equity is 8.92%, which is 27% below median its own 10-year median of 12.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Themis Medicare stock overvalued right now?
Based on GuruFocus' analysis, Themis Medicare (NSE:THEMISMED) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹149.38, compared to a current price of ₹105.78 — trading 29.2% below its estimated fair value. The current Return-on-Tangible-Equity is 8.92%, which is 27% below median its 10-year median of 12.29 and 13% above the Drug Manufacturers industry median of 7.90. Themis Medicare's overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Themis Medicare (NSE:THEMISMED), the current Return-on-Tangible-Equity is 8.92% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Themis Medicare (NSE:THEMISMED) Overvalued in 2026?
Based on GuruFocus' analysis, Themis Medicare stock appears to be undervalued.
The current stock price of ₹105.78 is trading 29.2% below its estimated GF Value™ of ₹149.38.
GuruFocus considers Themis Medicare to be Modestly Undervalued.
Key valuation signals for NSE:THEMISMED:
Return-on-Tangible-Equity: 8.92% (27% below median its 10-year median of 12.29)
GF Value™: ₹149.38 vs. price of ₹105.78 (29.2% below fair value)
Industry Position: 13% above the Drug Manufacturers median (#635 of 900)
No single metric tells the full story. See the NSE:THEMISMED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Themis Medicare Ltd is an Indian based company engaged in the manufacturing and marketing of pharmaceutical products. The Company operates only in one business segment which is Pharmaceuticals. Geographically, it derives a majority of revenue from India and also has a presence in the international market. Its product categories include Anti Malarial, CCD products, Nutritional Gummies, and Candy and Other Products such as OD-LM, Dexem, Medzol and Tazowin.
74GF Score
Get the complete analysis for NSE:THEMISMED
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:THEMISMED has been successfully added to your 
